Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-25T17:29:59.531Z Has data issue: false hasContentIssue false

Disruptive behaviour's treatment with paliperidone in autistic disorder: Review and case report

Published online by Cambridge University Press:  23 March 2020

M. García Moreno*
Affiliation:
Hospital Universitario Puerta de Hierro Majadahonda, CSM Majadahonda, Madrid, Spain
A. De Cós Milas
Affiliation:
Hospital Universitario de Móstoles, CSM Móstoles, Madrid, Spain
L. Beatobe Carreño
Affiliation:
Hospital Universitario de Móstoles, CSM Móstoles, Madrid, Spain
B. Poza Cano
Affiliation:
Hospital Universitario El Escorial, CE San Carlos El Escorial, Madrid, Spain
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Autistic disorder (AD) is a neuropsychiatric disorder that often presents significant disruptive symptoms such as irritability, aggression and self-injury in addition to impairment of social skills and communication. These symptoms interfere both individuals with AD and their families and social environment.

Objective

Show paliperidone effect in behavioural symptoms in AD.

Methods

Literature review about behavioural symptoms in AD and paliperidone effect in its treatment, followed by a case report of clinical improvement after treatment with paliperidone in a patient with autism. Agitation subscale Aberrant Behavior Checklist (ABC-I) scores was compared prior and 4 weeks after paliperidone treatment, and clinical improvement was assessed with Clinical Global Impression-Improvement Scale (CGI-I).

Results

Although risperidone has been one of the most studied atypical antipsychotic to treat this symptoms, its use should be limited in order to avoid extrapyramidal and metabolic symptoms. Paliperidone – the major metabolite of risperidone – has shown effectiveness in the treatment of behavioral symptoms in patients with autism, even in subjects with a prior ineffective trial of risperidone. Our patient, 21-years-old male with AD and significant disruptive symptoms was treated with paliperidone 9 mg/day. We observed a 20-points reduction in ABC-I scores 4 weeks later, with most significant improvement in items like auto-agression, heteroaggressivity, irritability and slams. CGI-I scores showed a much better improvement, and no significant adverse effects appeared.

Conclusions

Paliperidone is an effective and safe treatment in behavioral symptoms associated to AD, with reduction in ABC-I subscale scores. More studies are needed to confirm our data.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV1386
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.